Company’s 36-month beta value is 0.95.Analysts have differing opinions on the stock, with 7 analysts rating it as a “buy,” 4 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for MIRM is 38.32M, and currently, short sellers hold a 16.78% ratio of that floaft. The average trading volume of MIRM on January 20, 2025 was 396.89K shares.
MIRM) stock’s latest price update
The stock of Mirum Pharmaceuticals Inc (NASDAQ: MIRM) has increased by 2.44 when compared to last closing price of 45.83. Despite this, the company has experienced a 13.63% gain in its stock price over the last five trading sessions. zacks.com reported 2025-01-16 that Mirum stock rallies this week on upbeat preliminary 2024 results, the 2025 outlook and anticipated pipeline goals.
MIRM’s Market Performance
Mirum Pharmaceuticals Inc (MIRM) has seen a 13.63% rise in stock performance for the week, with a 10.76% gain in the past month and a 18.02% surge in the past quarter. The volatility ratio for the week is 5.23%, and the volatility levels for the past 30 days are at 3.62% for MIRM. The simple moving average for the past 20 days is 10.08% for MIRM’s stock, with a 28.62% simple moving average for the past 200 days.
Analysts’ Opinion of MIRM
Many brokerage firms have already submitted their reports for MIRM stocks, with Stifel repeating the rating for MIRM by listing it as a “Buy.” The predicted price for MIRM in the upcoming period, according to Stifel is $48 based on the research report published on April 17, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see MIRM reach a price target of $58, previously predicting the price at $60. The rating they have provided for MIRM stocks is “Buy” according to the report published on December 18th, 2023.
JP Morgan gave a rating of “Overweight” to MIRM, setting the target price at $37 in the report published on November 20th of the previous year.
MIRM Trading at 8.62% from the 50-Day Moving Average
After a stumble in the market that brought MIRM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -3.97% of loss for the given period.
Volatility was left at 3.62%, however, over the last 30 days, the volatility rate increased by 5.23%, as shares surge +10.08% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +16.07% upper at present.
During the last 5 trading sessions, MIRM rose by +13.63%, which changed the moving average for the period of 200-days by +86.24% in comparison to the 20-day moving average, which settled at $42.65. In addition, Mirum Pharmaceuticals Inc saw 13.54% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MIRM starting from Radovich Peter, who sale 1,998 shares at the price of $42.82 back on Jan 07 ’25. After this action, Radovich Peter now owns 27,015 shares of Mirum Pharmaceuticals Inc, valued at $85,545 using the latest closing price.
Peetz Christopher, the CHIEF EXECUTIVE OFFICER of Mirum Pharmaceuticals Inc, sale 7,489 shares at $42.82 during a trade that took place back on Jan 07 ’25, which means that Peetz Christopher is holding 119,359 shares at $320,644 based on the most recent closing price.
Stock Fundamentals for MIRM
Current profitability levels for the company are sitting at:
- -0.3 for the present operating margin
- 0.73 for the gross margin
The net margin for Mirum Pharmaceuticals Inc stands at -0.32. The total capital return value is set at -0.17. Equity return is now at value -38.83, with -14.76 for asset returns.
Based on Mirum Pharmaceuticals Inc (MIRM), the company’s capital structure generated 0.58 points at debt to capital in total, while cash flow to debt ratio is standing at -0.0. The debt to equity ratio resting at 1.37. The interest coverage ratio of the stock is -6.54.
Currently, EBITDA for the company is -136.49 million with net debt to EBITDA at -1.56. When we switch over and look at the enterprise to sales, we see a ratio of 7.65. The receivables turnover for the company is 4.48for trailing twelve months and the total asset turnover is 0.46. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.34.
Conclusion
In a nutshell, Mirum Pharmaceuticals Inc (MIRM) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
